A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 (AP505) Injection in the Treatment of Advanced Malignant Solid Tumors
- Trial Identifier: NCT06723964
- Study Design: Multicenter, open-label Phase IIa, evaluating efficacy and safety in advanced malignant solid tumors. It includes screening, treatment, and follow-up periods, with enrollment in cohorts based on tumor types across three stages (starting with 5 patients per cohort in Stage I, expanding in later stages up to 60 patients in one cohort).
- Indication: Advanced solid tumors
- Recurrent Platinum-resistant Epithelial Ovarian Cancer
- Triple Negative Breast Cancer (TNBC)
- Cervical Cancers
- Small Cell Lung Cancer
- Hepatocellular Carcinoma (HCC)
- Cholangiocarcinoma
- Colorectal Cancer
- Non-Squamous Non-Small Cell Lung Cancer
